Opdualag – a fixed-dose combination of LAG-3 inhibitor relatlimab and BMS' PD-1 inhibitor Opdivo (nivolumab) – was approved as a first-line therapy for unresectable or metastatic melanoma by ...

从二月起，黑色素瘤治疗药物Opdualag将更加便宜。 正在为黑色素瘤晚期治疗支付数十万澳元的澳大利亚人很快就能获得药品费用削减。 在澳大利亚 ...

The US regulator cleared BMS' LAG-3 drug relatlimab as a fixed-dose combination with its PD-1 inhibitor Opdivo (nivolumab) – under the Opdualag brand name – in patients aged 12 or over with ...

This latest immunotherapy drug, known as Opdualag, will be included in the PBS from February 1, making it available to about 940 patients across the country at a government-subsidised price.

A new drug combination that can spare skin cancer patients from the gruelling side effects of current treatments has been approved by health regulators. Sold under the brand name Opdualag, the ...